Proteros and Hutchison MediPharma enter into long-term research collaboration agreement
Proteros Biostructures GmbH announced that they entered into a substantial research collaboration agreement with Hutchison MediPharma Limited (HMP), whereby Proteros will support HMP’s drug discovery process throughout 2011 and beyond.
Under the agreement Proteros initially will provide high quality crystallography services on certain projects to support HMP’s drug discovery projects. HMP is focused on the areas of oncology and autoimmune diseases. Proteros will support HMP’s discovery research with Protein-Ligand-structure analysis throughout 2011 and beyond with selected compounds from HMP. This collaboration will significantly accelerate HMP’s drug discovery process, particularly in medicinal chemistry.
Cony D’Cruz, Chief Business Officer and President Proteros US, Inc. stated, “We are very pleased to be selected by Hutchison MediPharma to work with it on its multitude of exciting targets and we believe that our in-depth structural biology expertise is particularly suited to accelerate its efforts in its target areas.”
Most read news
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
A Trojan Horse delivery for treating a rare, potentially deadly, blood-clotting disorder - In this possible treatment, platelet blood cells carry an enzyme needed to prevent clots in TTP, while hiding the enzyme from autoantibody neutralization
CRELUX and ProQinase establish joint crystal-grade kinase protein and structures platform
Novel HCMV compound of AiCuris in phase IIb trial with bone marrow transplant recipients
Basilea receives milestone payment from distribution agreement for Toctino with Almirall
Biotage AB and McMaster University sign joint agreement to develop new chemistry platform
Asia-Pacific continues to drive global healthcare investment, innovation and growth ASEAN - A US$150 billion healthcare market by 2017, says Frost & Sullivan
Pharmacogenomics study finds rare gene variants critical for personalized drug treatment

Cambridge-based Startup Develops World’s Fastest Coronavirus-Killing Antiviral Protection
Evolva shareholders approve all Board proposals in AGM: Green light for Abunda acquisition
Aragen Bioscience, Inc. and CEVEC Sign License Agreement for Human CAP and CAP-T Technology
